These biomarkers are broadly categorized into predictive, such as specific receptors in breast cancer and EGFR in metastatic non-small cell lung cancer 35 and prognostic, which indicate disease progression, recurrence, or mortality 36. This evidence concerns the gene EGFR and breast carcinoma.